Mark Brandt

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Letter to Editor Recurrent pathogenic mutations in IDH1 and IDH2 at the conserved amino acid sites IDH1-R132, IDH2-R140 and IDH2-R172 occur in approximately 20% of patients with acute myeloid leukemia (AML).(1) A recent analysis of AML patients at our institution identified IDH1/2 mutations in 20% (n=167) of 826 AML patients, with IDH1/2 mutations occurring(More)
for generously providing data. All remaining errors are mine. Abstract Asset pricing models based on rational time-varying expected returns and equity characteristics impose a restriction on stock return predictability. We provide a framework for investigating the restriction using an economic metric based on asset allocation decisions in the presence of(More)
  • 1